Delivery Order SPE2DB22D1106-SPE2DB25FEZN2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,578.09 to AmerisourceBergen Drug Corp for Sprycel 50 mg tablets (60-count) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026. The...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $18,543.22 to AmerisourceBergen Drug Corp for the supply of Sprycel 70 mg tablets (60-count units). This competitive award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, utilizes firm fixed pricing with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Sprycel 140mg tablets (30-count packages) valued at $11,140.74. This non-competitive, firm fixed-price delivery order is scheduled for completion by October 9, 2025, with performance at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $5,665.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Sprycel 100 mg tablets (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitive award carries no set-aside designation and is to be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical supply vendor, fulfills this order as a...
- The Defense Logistics Agency awarded a delivery order valued at $12,785.44 to AmerisourceBergen Drug Corp for the supply of Sprycel 100 mg tablets (30-count) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price, non-set-aside contract is classified as a delivery order and will be performed at the contractor's location in Conshohocken, Pennsylvania. Sprycel is a targeted cancer therapy medication, reflecting the Defense Logistics Agency's ongoing...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for 30 tablets of Sprycel 100 mg, a targeted cancer therapy medication, with a ceiling value of $17,467.68. The contract was awarded on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a firm fixed-price procurement. This delivery order is classified as a child contract, indicating it was issued under a larger umbrella agreement. The work will be performed at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,013.24 on July 25, 2025, for the supply of Sprycel 100 mg tablets (30-count packages). This competitively awarded, firm fixed-price contract is non-set-aside and specifies a completion date of July 28, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $16,333.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Sprycel 50 mg, a targeted cancer therapy medication. The contract was competitively awarded without set-asides and is scheduled for completion by September 17, 2025. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which...
- The Defense Logistics Agency awarded a delivery order valued at $38,472.49 to AmerisourceBergen Drug Corp for the supply of Sprycel 100 mg tablets (30-count packages) under a firm fixed-price contract type. The award was made on August 29, 2025, with an ultimate completion date of September 2, 2025, and represents a non-competitive delivery order against an existing contract vehicle. Performance will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Sprycel 100 mg tablets (30-count units) with a ceiling value of $41,700.72. This firm fixed-price delivery order, awarded on August 28, 2025, represents a non-competitive, non-set-aside procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. As a child contract, this delivery order...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEZN2Delivery Order
The Defense Logistics Agency awarded a $5,777.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Sprycel 80 mg tablets (30-count). This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The performance location is listed as Conshohocken, Pennsylvania, the company's headquarters, with an ultimate completion date of July 25, 2025. Sprycel is a targeted cancer therapy used in treating chronic myeloid leukemia and acute lymphoblastic leukemia, reflecting the breadth of specialty pharmaceutical products the company supplies to federal medical procurement. AmerisourceBergen Drug Corp, headquartered in Pennsylvania, serves as a critical vendor for the Defense Health Agency and other federal healthcare systems through its comprehensive pharmaceutical distribution network. The company's SPE2DX IDC vehicle enables flexible sourcing of a wide range of pharmaceutical products, generic and brand-name medications, vaccines, and medical supplies to support military healthcare programs globally. This delivery order exemplifies the company's role in fulfilling specialized medical supply requirements across the Department of Defense healthcare enterprise, supporting military personnel and beneficiaries' access to essential pharmaceuticals and oncology treatments.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 7/24/25 |